PET of HER2-positive pulmonary metastases with 18F-ZHER2:342 affibody in a murine model of breast cancer: comparison with 18F-FDG.
PET of HER2-positive pulmonary metastases with 18F-ZHER2:342 affibody in a murine model of breast cancer: comparison with 18F-FDG.
复制标题
DOI：
10.2967/jnumed.111.100354
复制
发表时间：
2012-06
期刊：
影响因子：
--
通讯作者：
Capala J
中科院分区：
文献类型：
--
作者：
Kramer-Marek G;Bernardo M;Kiesewetter DO;Bagci U;Kuban M;Aras O;Zielinski R;Seidel J;Choyke P;Capala J
靶向治疗通常取决于肿瘤中存在的靶标的表达。这种表达在广泛转移中可能难以确定。18F-FDG PET/CT虽然敏感，但对特定肿瘤标志物无特异性。在此，我们比较了人表皮生长因子受体2（HER 2）特异性18F-ZHER 2：342-Affibody和18F-FDG在乳腺癌小鼠模型中表达HER 2的肺转移中的应用。通过尾静脉注射MDA-MB-231 HER 2-Luc人乳腺癌细胞建立肺转移模型。生物发光成像用于评估转移进展。通过PET图像与MR和CT图像的共配准来确认18F-ZHER 2：342-亲和体和18F-FDG的摄取。在研究结束时，通过免疫组织化学和放射自显影离体评估肺组织中肿瘤细胞和HER 2表达的存在以及示踪剂的分布。18F-ZHER 2：342-亲和体成功靶向肺中的HER 2阳性病变，并允许早在注射细胞后9周检测到转移。相反，18F-FDG摄取常常被周围的炎症改变所掩盖，并且对HER 2表达是非特异性的。细胞水平的HER 2表达与放射自显影的示踪剂摄取密切相关。18 F-ZHER 2：342-亲和体是一种很有前途的示踪剂，可用于评估乳腺癌转移的HER 2状态，并且比18 F-FDG更能特异性地检测HER 2阳性病变。
Targeted therapies often depend on the expression of the target present in the tumor. This expression can be difficult to ascertain in widespread metastases. 18F-FDG PET/CT, although sensitive, is nonspecific for particular tumor markers. Here, we compare the use of a human epidermal growth factor receptor 2 (HER2)–specific 18F-ZHER2:342-Affibody and 18F-FDG in HER2-expressing pulmonary metastases in a murine model of breast cancer. The lung metastasis model was established by intravenous injection of MDA-MB-231HER2-Luc human breast cancer cells into the tail vein. Bioluminescence imaging was used to evaluate metastasis progression. Uptake of 18F-ZHER2:342-Affibody and 18F-FDG was confirmed by coregistration of the PET images with MR and CT images. At the end of the study, the presence of neoplastic cells and HER2 expression in lung tissues, and distribution of the tracer, were assessed ex vivo by immunohistochemistry and autoradiography. 18F-ZHER2:342-Affibody successfully targeted HER2-positive lesions in the lung and allowed detection of metastases as early as 9 wk after injection of cells. In contrast, 18F-FDG uptake was often masked by surrounding inflammatory changes and was nonspecific for HER2 expression. HER2 expression at a cellular level correlated well with tracer uptake on autoradiography. 18F-ZHER2:342-Affibody is a promising tracer for evaluation of HER2 status of breast cancer metastases and is more specific for detecting HER2-positive lesions than 18F-FDG.
登录
查看更多内容
影响因子：
1.9
作者：
Kiesewetter, Dale O.;Kramer-Marek, Gabriela;Ma, Ying;Capala, Jacek
通讯作者：
Capala, Jacek
DOI：
10.1007/s00259-007-0658-0
发表时间：
2008-05
影响因子：
9.1
作者：
Kramer-Marek, Gabriela;Kiesewetter, Dale O.;Martiniova, Lucia;Jagoda, Elaine;Lee, Sang Bong;Capala, Jacek
通讯作者：
Capala, Jacek
DOI：
10.1158/1078-0432.ccr-09-0636
发表时间：
2009-12-15
期刊：
Clinical cancer research : an official journal of the American Association for Cancer Research
影响因子：
--
作者：
Pohlmann PR;Mayer IA;Mernaugh R
通讯作者：
Mernaugh R
DOI：
10.1073/pnas.1005025107
发表时间：
2010-08-24
影响因子：
11.1
作者：
Eigenbrot, Charles;Ultsch, Mark;Hard, Torleif
通讯作者：
Hard, Torleif
影响因子：
11.2
作者：
Orlova, Anna;Tolmachev, Vladimir;Feldwisch, Joachim
通讯作者：
Feldwisch, Joachim